Atlas Trials

Efficacy and Safety of CD19CD20-CAR.p40-T in B-cell Lymphoma

Clinical trial NCT07097207 · RECRUITING

Trial details

NCT number
NCT07097207
Sponsor
Shenzhen University General Hospital
Status
RECRUITING
Phase
Phase 1, Phase 2
Study type
INTERVENTIONAL
Relapsed/Refractory B-cell Lymphoma
Start date
2023-10-01
Primary completion
2026-09-30
Enrollment
20

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.